The growth suppressive activity of the retinoblastoma tumour suppressor protein is controlled by cell cycle dependent phosphorylation. However, while many in vivo phosphorylation sites have been mapped, the identities of those residues whose phosphorylation is regulated remain elusive. We have mapped the epitopes of three independent monoclonal antibodies that recognise a distinction between dierentially phosphorylated pRB sub-populations. All three antibodies recognise an identical epitope which encompasses an essential serine positioned within a consensus site for proline directed kinase phosphorylation. We provide evidence that this residue, serine 608 of pRB, is an authentic phosphorylation site that can be phosphorylated in vitro by cyclin A-CDK2 and cyclin D1-CDK4 kinases but not by cyclin E-CDK2 kinase or the mitogen activated kinase ERK2. Phosphorylation at this residue seems to be cell cycle regulated, occurring prior to entry into the S phase.
The growth suppressive activity of the retinoblastoma tumour suppressor protein is controlled by cell cycle dependent phosphorylation. However, while many in vivo phosphorylation sites have been mapped, the identities of those residues whose phosphorylation is regulated remain elusive. We have mapped the epitopes of three independent monoclonal antibodies that recognise a distinction between dierentially phosphorylated pRB sub-populations. All three antibodies recognise an identical epitope which encompasses an essential serine positioned within a consensus site for proline directed kinase phosphorylation. We provide evidence that this residue, serine 608 of pRB, is an authentic phosphorylation site that can be phosphorylated in vitro by cyclin A-CDK2 and cyclin D1-CDK4 kinases but not by cyclin E-CDK2 kinase or the mitogen activated kinase ERK2. Phosphorylation at this residue seems to be cell cycle regulated, occurring prior to entry into the S phase.
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The retinoblastoma tumour suppressor gene encodes a 105 kDa nuclear phosphoprotein, pRB. The growth controlling function of pRB is mediated through its interaction with transcription factors involved in cell cycle progression and cell dierentiation (for review see Weinberg, 1995) . This ability to bind transcription factors is regulated by cell cycle dependent phosphorylation. The likely mediators of pRB regulation are members of the family of proline-directed, serine/ threonine, cyclin dependent kinases (CDKs); they phosphorylate authentic sites on pRB and are themselves thought to play a key role in cell cycle control (for reviews see Sherr, 1993; Hunter and Pines, 1994) .
Cellular pRB runs as a smear of many bands on SDS-containing polyacrylamide gels, indicative of a number of dierentially phosphorylated species. The pattern of phosphorylated forms changes as cells progress through the cell cycle, suggesting that the regulation of pRB phosphorylation is a multi-stage process (Buchkovich et al., 1989; DeCaprio et al., 1992) . While pRB may be basally phosphorylated on a number of its ser/thr-pro motifs, tryptic phosphopeptide mapping of dierent forms of pRB has demonstrated that changes in its activity and migration are associated with phosphorylation at additional residues (DeCaprio et al., 1992; Mittnacht et al., 1994) . However, while some in vivo phosphorylation sites have been mapped , the identities of those residues whose phosphorylation is regulated remain elusive.
In our search for cell cycle regulated pRB phosphorylation sites we decided to investigate monoclonal antibodies that recognise a distinction between differentially phosphorylated pRB sub-populations. Hu and coworkers have previously prepared and characterised a number of anti-pRB monoclonal antibodies using, as an antigen, a bacterially produced fusion protein of Nterminally truncated pRB (amino acids 387 ± 928). Several of these were speci®c for the form of pRB that migrates fastest on SDS-containing gels, widely referred to as underphosphorylated pRB (Hu et al., 1991) . We have con®rmed that two of these underphosphorylated pRB-speci®c antibodies (XZ37 and XZ105) immunoprecipitate only the fast migrating form of pRB, unlike other antibodies (e.g. 21C9) which recognise all forms of pRB ( Figure 1a ). In addition, both these antibodies, as well as a third, commercially available antibody (14441a, PharMingen), speci®cally recognise underphosphorylated pRB in Western blots following denaturing SDSpolyacrylamide gel electrophoresis (PAGE) (Figure 1b and data not shown).
The fast migrating, underphosphorylated form of pRB seems to be the one active in growth suppression. This distinction between the underphosphorylated form and the other, slower migrating forms of hyperphosphorylated pRB was ®rst observed with respect to the pRB-neutralising eect of SV40 large T antigen and the eects of pRB itself on the transcription factor E2F. These eects are mediated through exclusive binding of these proteins to underphosphorylated pRB (Ludlow et al., 1989; Chellappan et al., 1991) . More recently, observations of such dierences in binding anities between the two subclasses of pRB have been extended; fractionation experiments demonstrate that, unlike hyperphosphorylated pRB, all the underphosphorylated pRB in a cell is tightly tethered to nuclear proteins (Mittnacht et al., 1994) .
Since separation of dierent pRB subgroups by fractionation relies on their dierent biochemical properties, it is a more stringent test for active pRB than simply assessing dierent mobilities on SDS-containing gels. We have therefore tested the three underphosphorylated pRB-speci®c antibodies for their recognition of pRB in such a fractionation experiment and ®nd that only material tethered to the nucleus is recognised (Figure 1c and data not shown). Thus the underphosphorylated pRB-speci®c antibodies recognise pRB that not only migrates dierently, but is also functionally distinct, from other forms of pRB.
We set out to map the epitopes of these three underphosphorylated pRB-speci®c antibodies since we reasoned that they were likely to encompass regulated phosphorylation sites. This seemed a more likely explanation for their speci®city than their recognising a conformational epitope (some unique aspect of ternary structure in underphosphorylated pRB), since antibody speci®city is retained after denaturing SDS ± PAGE, which destroys the native ternary structure of proteins.
To narrow down the regions recognised by these antibodies, we tested antibody reactivity for a series of pRB fragments, expressed as glutathione-S-transferase (GST) fusions in bacteria (Figure 2 and Table 1 ). We found that all three underphosphorylated pRB-speci®c antibodies (XZ37, XZ105 and 14441a) speci®cally recognise a small fragment embracing the spacer between the two domains of the pRB oncogenebinding pocket (amino acids 560 to 670) and fail to recognise a fragment comprising of the pocket region from which this spacer has been deleted (amino acids 379 ± 792 D573 ± 645).
Immunoprecipitations a b c Figure 1 Underphosphorylated pRB-speci®c antibodies are speci®c for fast migrating, nuclear tethered pRB. (a) Immunoprecipitation of fast migrating pRB. pRB was immunoprecipitated from semi-con¯uent WI38 cells as previously described . Whole cell lysate (lane 1), lysate immunoprecipitated with one of the two underphosphorylated pRB-speci®c antibodies; XZ37 (lane 2) or XZ105 (lane 3), or lysate immunoprecipitated with a monoclonal antibody recognising all forms of pRB ; 21C9 (lane 4) were resolved by SDS ± PAGE and pRB detected by Westen blotting with anti-pRB speci®c rabbit sera. (b) Recognition of fast migrating pRB in Western blots. Semi-con¯uent HaCat cells were lysed into ELB + (10 mM HEPES, pH 7.0; 25 mM NaCl; 10 mM KCl; 10 mM EDTA; 1.5 mM MgCl 2 ; 1 mM DTT; 0.1% Triton; beta-glycerophosphate and protease inhibitors; aprotinin, PMSF and leupeptin). Clari®ed supernatants were resolved by SDS ± PAGE and analysed by Western blotting using either apRB antibodies that recognise all forms of pRB (a mix of 14001a (PharMingen) and anti-pRB speci®c rabbit sera) or the underphosphorylated pRB-speci®c antibody, XZ37. (c) Recognition of nuclear tethered pRB. Cell fractionation of semi-con¯uent WI38 cells was performed as previously described . Total cell extract (Total, lane 1), low salt soluble supernatant (Soluble, lane 2) and nuclear pellet (Tethered, lane 3) were resolved by SDS ± PAGE and analysed by Western blotting using either a-pRB antibodies that recognise all forms of pRB (see legend to b) or the underphosphorylated pRB-speci®c antibody, XZ37 Puri®ed proteins of GST fused to the regions of human pRB corresponding to the amino acids indicated were resolved by SDS ± PAGE and analysed by Western blotting using either anti-GST speci®c rabbit sera (a) or the underphosphorylated pRBspeci®c antibodies; XZ37 (b), XZ105 (c), and 14441a (d). GST fusion proteins were puri®ed from the E. coli strain X11 blues essentially as described for other GST-RB fusion proteins . pRB fragments containing internal deletions are de®ned as follows; Dsp describes the pRB spacer deletion of amino acids 573 ± 645; D21 and D22 describe deletions of the amino acids encoded by exons 21 and 22 of the pRB coding sequence respectively pRB antibodies identify a regulated phosphorylation site T Zarkowska et al Notably, the antibodies recognise two fusion proteins harbouring tumour-derived mutations which severely disrupt pRB conformation (i.e. deletions of exons 21 or 22 of the gene), a further indication that they are unlikely to recognise conformational epitopes in underphosphorylated pRB.
In order to determine the exact epitopes recognised, we employed a peptide scanning approach which takes advantage of a technique allowing simultaneous synthesis of multiple peptides on a membrane. Such membranes, coated with spots of peptides covalently attached via their carboxy-termini, can subsequently be assayed for antibody reactivity using a beta-galactosidase-conjugated secondary antibody to visualise interactions. We homed in on the sites of recognition by testing a series of overlapping, ten amino acid peptides scanning the pRB spacer implicated in our initial mapping as the region containing the epitopes ( Figure  3a) .
The results were identical for all three antibodies (shown in Figure 3b for XZ37); all three recognise the same peptide, spanning amino acids 603 ± 613 of pRB. Moreover, this peptide encompasses two consensus phosphorylation sites for proline-directed kinases (serines 608 and 612 of pRB), suggesting that the speci®city of these antibodies may be due to their direct recognition of one of these residues.
In order to determine whether either one of the serines was central to antibody recognition, we designed a second series of peptides representing a smaller region around amino acids 603 ± 613, each overlapping by only one amino acid (Figure 3c ). In anticipation that one of the two serines would be central to antibody recognition, we also tested peptides with amino acid changing at these two residues ( Figure  3d) .
The results shown are those for XZ105, but were again identical for all three antibodies; only those peptides containing the sequence YLSPVR, encompassing serine 608 of pRB, are recognised. Furthermore, antibody reactivity is entirely lost when this serine is replaced by other amino acids (threonine, alanine, aspartic acid or glutamic acid). In contrast, peptides with similar changes at serine 612 retain full reactivity.
Therefore, all three of these underphosphorylated pRB-speci®c antibodies recognise an identical epitope; YLSPVR. Serine 608 is not only central to the epitope but is itself an important determinant for antibody recognition. The smallest change to this serine (the addition of a single methyl group in forming threonine or the ablation of a hydroxyl group in the change to alanine) prevent recognition. Accordingly, the most likely explanation for the speci®city of the antibodies is that recognition is determined by the phosphorylation status of serine 608, whereby only pRB un-phosphorylated at this residue is detected.
If the above holds true, one would predict that a kinase capable of phosphorylating pRB at residue 608 could directly mask the epitope of the underphosphorylated pRB-speci®c antibodies. The consensus sequence around serine 608 implicates proline directed kinases, possibly from the CDK family, as potential candidates for its phosphorylation. We have therefore tested such kinases for their ability to mask the antibody epitope upon in vitro phosphorylation.
We ®rst tested cyclin A-CDK2, a CDK which has previously been shown to release pRB from nuclear tethering upon in vitro phosphorylation (Mittnacht et al., 1994) . We assayed this kinase by observing the eect of its phosphorylation on puri®ed GST-RB(1 ± 928). We ®nd that cyclin A-CDK2 can directly mask the YLSPVR epitope in GST-RB upon phosphorylation and in a time dependent manner (Figure 4a) .
Although cyclin A-CDK2 may have a role in maintaining hyperphosphorylation of pRB in the S and G 2 phases, hyperphosphorylated pRB is ®rst seen at a point in the cell cycle before cyclin A-CDK2 kinase activity can be detected (Mittnacht et al., 1994) . This enzyme is therefore an unlikely candidate for masking of the YLSPVR epitope upon the initial conversion of pRB into a hyperphosphorylated form during the cell cycle. We have therefore tested three other proline directed kinases (cyclin D1-CDK4, cyclin E-CDK2 and ERK2) whose activities are believed to be maximal at cell cycle stages previous to, or concomitant with, pRB hyperphosphorylation. Cyclin D1-CDK4 and cyclin E-CDK2 are two CDKs that are likely candidates for pRB hyperphosphorylation at the G 1 cell cycle checkpoint (Weinberg, 1995) . The mitogen Figure 2 . Schematics show the regions of pRB tested. Shaded regions denote the pRB pocket and bars above the schematics indicate consensus sites for proline directed kinases. Numbers refer to the amino acid sequence of pRB pRB antibodies identify a regulated phosphorylation site T Zarkowska et al activated kinase, ERK2, is a non-CDK proline directed kinase implicated in controlling progression from G 0 to G 1 phase (for review see Marshall, 1994) . When we tested these three kinases we found that, upon phosphorylating GST-pRB to a similar degree, they had dierent eects on antibody recognition (Figure 4b ). While cyclin D1-CDK4 phosphorylation masks the epitope, cyclin E-CDK2 phosphorylation does not. This is despite the apparent ability of cyclin (1 ± 928) was incubated for the indicated times with enzyme and MnCl 2 150 mM ATP in kinase buer (50 mM HEPES-KOH, pH 7.0; 10 mM MgCl 2 ; 10 mM; 1 mM DTT plus protein kinase A inhibitor (Sigma), beta-glycerophosphate and protease inhibitors; aprotinin, PMSF, leupeptin). Additional enzyme and ATP were added every 10 min and the reactions stopped with SDScontaining sample buer. Proteins were separated by SDS ± PAGE and analysed by Western blotting using either the underphosphorylated pRB-speci®c antibody, XZ37, or an a-pRB antibody that recognises all forms of pRB (14001a, Pharmingen). GST-pRB(1 ± 928) was expressed and puri®ed from the E. coli strain BL21 (PlysS) essentially as described for other GST fusion proteins with the following modi®cations; cells were lysed by freeze thawing and DNA was broken down by DNAse1 digestion instead of sonication. Lysates from insect cells overexpressing baculovirus-encoded CDK2, cyclin A or both kinase subunits were used as controls or enzyme respectively as previously described for other CDKs (Kato et al., 1993) . (b) Cyclin D1-CDK4, ERK2 and cyclin E-CDK2 kinases were assayed for epitope masking as described above with the following exceptions; only the 40 min time point was taken; the ATP used in the experiment was spiked with a small amount of g-32 P-labelled ATP; and ERK2 was tested in an optimal Trisbased kinase buer, described elsewhere (Bott et al., 1994) . Proteins were separated by SDS ± PAGE and analysed by Western blotting using either the underphosphorylated pRB-speci®c antibody, XZ37, or an a-pRB antibody that recognises all forms of pRB (14001a, Pharmingen). ATP incorporation was assayed by exposing dried blots to X-ray ®lm for 3 days. Cyclin D1-CDK4, cyclin E-CDK2 and their appropriate controls were made in insect cells as for cyclin A-CDK2. Recombinant ERK2, produced in E. coli, was activated by E. coli derived, constitutively active GST-EEMAPKK as described elsewhere (Bott et al., 1994) . GST-EEMAPKK and non-activated ERK2 were used as controls pRB antibodies identify a regulated phosphorylation site T Zarkowska et al E-CDK2 to induce a hyperphosphorylation-type shift in the electrophoretic mobility of its GST-pRB substrate, indistinguishable from that induced by cyclin D1-CDK4 (see middle panel). Similarly, ERK2 is incapable of masking the YLSPVR epitope under these conditions. Thus, serine 608 phosphorylation may not only be limited to the CDK family of kinases but also, perhaps surprisingly, to speci®c members of this family.
Having obtained evidence that serine 608 was an in vitro phosphorylation site for CDKs we looked for further proof that it could also be utilised in vivo. pRB mutated at certain of its authentic, in vivo phosphorylation sites does not give the full complement of phosphorylated pRB species seen on SDS ± PAGE gels (Hamel et al., 1992; Kato et al., 1993; Knudsen et al., 1996) . To test the eect of such a mutation at serine 608, we have expressed a serine 608 alanine (S608A) point mutated pRB in insect cells. On expression, this mutant does not fully reproduce the pattern of phosphorylated bands seen with wild type pRB ( Figure 5 ). Moreover, on co-expression with a hyperphosphorylating kinase such as cyclin D1-CDK4, it does not achieve the same levels of hyperphosphorylation as does wild type pRB, providing further evidence that serine 608 is a genuine, in vivo pRB phosphorylation site.
In summary, it would seem that the underphosphorylated pRB-speci®c antibodies recognise only the sub-population of pRB which is un-phosphorylated at serine 608, a residue which appears to be a genuine target for certain members of the CDK family of cell cycle regulating kinases. Thus, these underphosphorylated pRB-speci®c antibodies can be used to determine the extent of serine 608 phosphorylation in cellular pRB. To this eect, we have made lysates of human keratinocyte derived, HaCat cells grown under dierent conditions and probed them for pRB harbouring the unmodi®ed YLSPVR epitope (Figure 6 ).
We ®nd signi®cant amounts of pRB reactive with the underphosphorylated pRB-speci®c antibody, XZ37, in lysate from HaCat cells cultured in the absence of serum or treated with TGF beta, conditions which both lead to arrest of these cells in the G 0 /G 1 compartment of the cell cycle (Belbrahem et al., 1996) . Addition of serum to previously serum-deprived cells results in masking of the epitope. This eect is, however, blocked by the translation inhibitor cycloheximide, implicating that active translation is required to generate pRB phosphorylated at serine 608. Cells blocked in the S phase of the cell cycle by thymidine treatment contain none of the unmodi®ed YLSPVR epitope, suggesting that serine 608 phosphorylation is complete prior to onset of S phase. We note that rapidly dividing cells contain very little, if any, pRB recognised by XZ37, hinting that pRB un-phosphorylated at serine 608 may be present for only a short time window or not at all in rapidly cycling cells.
Thus, the phosphorylation status of serine 608 in a cell seems to depend on its cell cycle position. Cells in the G 0 /G 1 compartment of the cycle are enriched for pRB un-phosphorylated at serine 608. Phosphorylation at this residue seems to occur prior to entry into S phase after which it remains phosphorylated throughout the rest of the cell cycle. WT S608A Figure 5 Hyperphosphorylation of serine 608 alanine point mutated pRB. Wild type pRB (WT) or a serine 608 alanine mutated pRB (S608A) were expressed in insect, Sf9 cells either singularly (lanes 1 and 3 respectively) or together with CDK4 and cyclin D1 (lanes 2 and 4) using the baculovirus expression system as described by others (King and Possee, 1992) . Cells were lysed in ELB + 48 h post-infection and the pRB visualised by SDS ± PAGE followed by Western blotting using a-pRB antibodies that recognise all forms of pRB (see legend to Figure 1b) pRB antibodies identify a regulated phosphorylation site T Zarkowska et al Interestingly, cells stimulated by serum in the presence of the translation inhibitor cycloheximide are not able to phosphorylate pRB at serine 608. This is consistent with our data that ERK2, a kinase whose activation is not impaired by the presence of cycloheximide upon serum stimulation (Sun et al., 1993) , cannot phosphorylate pRB at this site. Thus ERK2 is unlikely to be responsible for masking the antibody epitope during cell cycle entry. This is in contrast to cyclin D1-CDK4 which, according to our data, can phosphorylate serine 608. The increase in its activity following serum stimulation is thought to depend on the de novo synthesis of both CDK4 and cyclin subunits (Baldin et al., 1993; Matsushime et al., 1994) , which would designate activation of this kinase sensitive to cycloheximide treatment. Thus CDK4 associated with cyclin D1, or possibly one of the other D-type cyclins, currently remains the most likely candidate for the activity mediating the cell-cycle dependent phosphorylation of serine 608.
Although regulation of pRB phosphorylation is known to be cell cycle dependent, serine 608 is the ®rst clearly identi®ed site at which such regulation has been demonstrated. Given the timing and occurrence of phosphorylation at this site, as well as the possible involvement of cyclin D1-CDK4 kinase, it will be interesting to see what contribution phosphorylation at serine 608 has to the changes in biochemical properties of pRB as a cell progresses through its cycle.
